Skip to main content
. 2017 May 15;2017(5):CD011673. doi: 10.1002/14651858.CD011673.pub2

Figure 5.

Figure 5

Forest plot of comparison: 3 Interferon (IFN‐α) alone versus IFN‐α plus bevacizumab in first‐line therapy of metastatic renal cell carcinoma, outcome: 3.1 1‐year mortality.